CF101
BRAND NAME: none yet
GENERIC NAME: none yet
EXPERIMENTAL/INTERNAL COMPANY NAME: CF101 |
|
| DRUG USE (P OR PsA) | METHOD OF DELIVERY | DEVELOPING COMPANY/COMPANIES |
| Plaque psoriasis | Oral (capsule) | Can-Fite Biopharma |
Description and Comments
CF101 is an anti-inflammatory drug (
targeting the Adenosine A3
receptor [A3AR] with the goal of suppressing TNF-alpha) currently undergoing testing for effectiveness against a variety of diseases including psoriasis, rheumatoid arthritis, and Crohn's Disease. A Phase II study evaluating the safety and effectiveness of CF101 in psoriasis patients was completed in September 2009. In this study about one-third of patients saw at least a 50% reduction in their psoriasis symptoms, and there were no significant safety problems.
Can-Fite Biopharma recently received US FDA approval for a new Phase II/III study in psoriasis.
Other News and Links
News item about upcoming Phase II/III trial:
FDA clears Can-Fite psoriasis clinical trial (6/6/10)
Related company press release:
Can-Fite Initiates Preparatory Work for Psoriasis Phase III Trial With CF101 (10/1/09)
Results of Phase II Study in Psoriasis Patients:
Treatment of Plaque-Type Psoriasis with Oral CF101: Data from an Exploratory Phase 2 Clinical Trial
